Evidence map›Paper›PMID 26789107›Full record

ArticleMolecular endocrinology (Baltimore, Md.)2016

Puerarin Protects Pancreatic β-Cells in Obese Diabetic Mice via Activation of GLP-1R Signaling.

Lei Yang, Dongdong Yao, Haiyuan Yang, Yingjie Wei, Yunru Peng, Yongfang Ding, Luan Shu

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular endocrinology (Baltimore, Md.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 73 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Lei YangAffiliated Hospital of Integrated Traditional Chinese and Western Medicine (L.Y., D.Y., Y.W., Y.P., Y.D., L.S.), Nanjing University of Chinese Medicine, Nanjing, 210028 China; Key Laboratory of New Drug Delivery System of Chinese Materia Medica (L.Y., D.Y., Y.W., Y.P., Y.D., L.S.), Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028 China; and Jiangsu Key Laboratory of Xenotransplantation (H.Y.), Nanjing Medical University, Nanjing, 210029 China.
Dongdong YaoAffiliated Hospital of Integrated Traditional Chinese and Western Medicine (L.Y., D.Y., Y.W., Y.P., Y.D., L.S.), Nanjing University of Chinese Medicine, Nanjing, 210028 China; Key Laboratory of New Drug Delivery System of Chinese Materia Medica (L.Y., D.Y., Y.W., Y.P., Y.D., L.S.), Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028 China; and Jiangsu Key Laboratory of Xenotransplantation (H.Y.), Nanjing Medical University, Nanjing, 210029 China.
Haiyuan YangAffiliated Hospital of Integrated Traditional Chinese and Western Medicine (L.Y., D.Y., Y.W., Y.P., Y.D., L.S.), Nanjing University of Chinese Medicine, Nanjing, 210028 China; Key Laboratory of New Drug Delivery System of Chinese Materia Medica (L.Y., D.Y., Y.W., Y.P., Y.D., L.S.), Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028 China; and Jiangsu Key Laboratory of Xenotransplantation (H.Y.), Nanjing Medical University, Nanjing, 210029 China.
Yingjie WeiAffiliated Hospital of Integrated Traditional Chinese and Western Medicine (L.Y., D.Y., Y.W., Y.P., Y.D., L.S.), Nanjing University of Chinese Medicine, Nanjing, 210028 China; Key Laboratory of New Drug Delivery System of Chinese Materia Medica (L.Y., D.Y., Y.W., Y.P., Y.D., L.S.), Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028 China; and Jiangsu Key Laboratory of Xenotransplantation (H.Y.), Nanjing Medical University, Nanjing, 210029 China.
Yunru PengAffiliated Hospital of Integrated Traditional Chinese and Western Medicine (L.Y., D.Y., Y.W., Y.P., Y.D., L.S.), Nanjing University of Chinese Medicine, Nanjing, 210028 China; Key Laboratory of New Drug Delivery System of Chinese Materia Medica (L.Y., D.Y., Y.W., Y.P., Y.D., L.S.), Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028 China; and Jiangsu Key Laboratory of Xenotransplantation (H.Y.), Nanjing Medical University, Nanjing, 210029 China.
Yongfang DingAffiliated Hospital of Integrated Traditional Chinese and Western Medicine (L.Y., D.Y., Y.W., Y.P., Y.D., L.S.), Nanjing University of Chinese Medicine, Nanjing, 210028 China; Key Laboratory of New Drug Delivery System of Chinese Materia Medica (L.Y., D.Y., Y.W., Y.P., Y.D., L.S.), Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028 China; and Jiangsu Key Laboratory of Xenotransplantation (H.Y.), Nanjing Medical University, Nanjing, 210029 China.
Luan ShuAffiliated Hospital of Integrated Traditional Chinese and Western Medicine (L.Y., D.Y., Y.W., Y.P., Y.D., L.S.), Nanjing University of Chinese Medicine, Nanjing, 210028 China; Key Laboratory of New Drug Delivery System of Chinese Materia Medica (L.Y., D.Y., Y.W., Y.P., Y.D., L.S.), Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028 China; and Jiangsu Key Laboratory of Xenotransplantation (H.Y.), Nanjing Medical University, Nanjing, 210029 China.
Jiangsu Provincial Academy of Traditional Chinese Medicine · CNNanjing University of Chinese Medicine · CNNanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes is characterized by a loss and dysfunction of the β-cell. Glucagon-like peptide 1 receptor (GLP-1R) signaling plays an important role in β-cell survival and function. It is meaningful to identify promising agents from natural products which might activate GLP-1R signaling. In this study, puerarin, a diet isoflavone, was evaluated its beneficial effects on β-cell survival and GLP-1R pathway. We showed that puerarin reduced the body weight gain, normalized blood glucose, and improved glucose tolerance in high-fat diet-induced and db/db diabetic mice. Most importantly, increased β-cell mass and β-cell proliferation but decreased β-cell apoptosis were observed in puerarin-treated diabetic mice as examined by immunostaining of mice pancreatic sections. The protective effect of puerarin on β-cell survival was confirmed in isolated mouse islets treated with high glucose. Further mechanism studies showed that the circulating level of GLP-1 in mice was unaffected by puerarin. However, puerarin enhanced GLP-1R signaling by up-regulating expressions of GLP-1R and pancreatic and duodenal homeobox 1, which subsequently led to protein kinase B (Akt) activation but forkhead box O1 inactivation, and promoted β-cell survival. The protective effect of puerarin was remarkably suppressed by Exendin(9-39), an antagonist of GLP-1R. Our study demonstrated puerarin improved glucose homeostasis in obese diabetic mice and identified a novel role of puerarin in protecting β-cell survival by mechanisms involving activation of GLP-1R signaling and downstream targets.

Indexed as

AnimalsCell SurvivalCytoprotectionDiabetes Mellitus, ExperimentalDiet, High-FatGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorGlucoseHyperglycemiaInsulin-Secreting CellsIsoflavonesLipid MetabolismMice, Inbred C57BLMice, ObeseSignal TransductionUp-RegulationGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorGlucoseIsoflavonespuerarin

Identifiers

PMID26789107
PMCPMC5414651
OpenAlexW2304013040

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.